GlassScriptPhysician profile
Steven D Cohen
NPI 1235115288
$8,707.12
in general payments reported to CMS, 2019-2025
36 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,816 · 2020: $468 · 2021: $1,077 · 2022: $1,964 · 2023: $1,333 · 2024: $849 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,800.00 | 2019-2021 | |
| Abbvie INC. | $1,208.80 | 2020-2024 | Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $724.09 | 2021-2025 | |
| Evofem Biosciences, INC. | $698.30 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $654.38 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $459.82 | 2021-2022 | |
| Exeltis, USA INC. | $431.51 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $326.00 | 2022-2025 | Veozah |
| Coopersurgical, INC. | $237.23 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $224.54 | 2019-2025 | Thinprep 2000 Processor |
| Roche Diagnostics Corporation | $195.65 | 2019 | |
| Biogen, INC. | $176.24 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $162.20 | 2022-2023 | Injectafer |
| Agile Therapeutics, INC. | $161.03 | 2021-2024 | Twirla |
| Lupin INC. | $134.60 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $113.63 | 2019 | |
| Therapeuticsmd, INC. | $111.52 | 2019-2022 | |
| Pfizer INC. | $109.53 | 2019-2024 | |
| Organon LLC | $105.94 | 2021-2024 | |
| Scynexis, INC. | $105.49 | 2022 | |
| Millicent US INC | $103.38 | 2021-2025 | Femlyv, Intrarosa |
| Virtus Pharmaceuticals LLC | $66.00 | 2021-2022 | |
| Travere Therapeutics, INC. | $50.27 | 2025 | |
| Shield Therapeutics INC | $43.07 | 2024-2025 | |
| Avion Pharmaceuticals | $37.67 | 2022 | |
| Corium, LLC | $34.02 | 2024-2025 | Azstarys |
| Allergan, INC. | $32.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.48 | 2024 | Gardasil 9, Gardasil |
| Harmony Biosciences LLC | $25.95 | 2024 | |
| Neurelis, INC. | $25.07 | 2024 | Valtoco |
| Ibsa Pharma INC. | $23.65 | 2022 | |
| Glaxosmithkline, LLC. | $21.61 | 2023 | Shingrix, Arexvy |
| Ascend Therapeutics US, LLC | $20.95 | 2022 | |
| Ucb, INC. | $17.41 | 2025 | Fintepla |
| Eisai INC. | $17.34 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.67 | 2023 | Adthyza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.